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From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral 
drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable. 
Currently, there are twenty-five anti-HIV compounds which have been formally approved for clinical use in 
the treatment of AIDS. These compounds fall into six categories: nucleoside reverse transcriptase inhibitors 
(NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), cell entry inhibitors or fusion inhibitors (FIs), co-receptor inhibitors 
(CRIs), and integrase inhibitors (INIs). Metabolism by the host organism is one of the most important 
determinants of the pharmacokinetic profile of a drug. Formation of active or toxic metabolites will also 
have an impact on the pharmacological and toxicological outcomes. Therefore, it is widely recognized that 
metabolism studies of a new chemical entity need to be addressed early in the drug discovery process. This 
paper describes an overview of the metabolism of currently available anti-HIV drugs.
Uniterms: AIDS/treatment. Drugs/anti-HIV. Drugs/metabolism. Antiretroviral drugs. Biotransformation.
Da identificação do HIV como o agente causador da AIDS, ao desenvolvimento de fármacos antirretrovirais 
eficazes, os avanços científicos na pesquisa sobre o HIV nos últimos vinte e seis anos foram marcantes. 
Atualmente, existem vinte e cinco fármacos anti-HIV formalmente aprovados pelo FDA para utilização 
clínica no tratamento da AIDS. Estes compostos são divididos em seis classes: inibidores nucleosídeos 
de transcriptase reversa (INTR), inibidores nucleotídeos de transcriptase reversa (INtTR), inibidores não-
nucleosídeos de transcriptase reversa (INNTR), inibidores de protease (IP), inibidores da entrada celular ou 
inibidores de fusão (IF), inibidores de co-receptores (ICR) e inibidores de integrase (INI). O metabolismo 
consiste em um dos maiores determinantes do perfil farmacocinético de um fármaco. A formação de 
metabólitos ativos ou tóxicos terá impacto nas respostas farmacológicas ou toxicológicas do fármaco. 
Portanto, é amplamente reconhecido que estudos do metabolismo de uma nova entidade química devem 
ser realizados durante as fases iniciais do processo de desenvolvimento de fármacos. Este artigo descreve 
uma abordagem do metabolismo dos fármacos anti-HIV atualmente disponíveis na terapêutica.
Unitermos: AIDS/tratamento. Fármacos/anti-HIV. Fármacos/antirretrovirais. Fármacos/metabolismo. 
Biotransformação.
INTRODUCTION
The human immunodeficiency virus (HIV) has 
been established as the causative agent of the acquired 
immunodeficiency syndrome (AIDS) for over twenty-
six years now (Barré-Sinoussi et al., 1983). During this 
time, an unprecedented success has been achieved in 
discovering anti-HIV drugs as reflected by the fact that 
there are now more drugs approved for the treatment 
of HIV than for all other viral infections put together 
(Mehellou, De Clercq, 2009). Despite this progress, the 
HIV pandemic remains one of the most serious challen-
ges to global health and is set to continue to be one of 
the leading causes of death and disability in the world 
for decades to come (Vitoria et al., 2009). Since 1983, 
C.H. Andrade, L.M. Freitas, V. Oliveira210
more than 60 million people have been infected with the 
virus, and more than 25 million people have died as a 
result (Cohen et al., 2008).
According to the World Health Organization 
(WHO), globally there were an estimated 33 million [30 
million–36 million] people living with HIV in 2007. Sub-
Saharan Africa remains the region most heavily affected 
by HIV, accounting for 67% of all people living with HIV 
and for 75% of AIDS deaths in 2007 (UNAIDS/WHO, 
2008). In addition, according to the same report, it was 
estimated that almost 3 mil lion HIV-infected people were 
receiving antiretroviral treatment in low- and middle-
income countries, representing approximately 31% of the 
estimated 9.7 million people currently in need of treatment 
(UNAIDS/WHO, 2008). 
Currently, there are twenty-five anti-HIV com-
pounds that have been formally approved for clinical 
use in the treatment of AIDS. These compounds fall into 
six categories: nucleoside reverse transcriptase inhibi-
tors (NRTIs), nucleotide reverse transcriptase inhibitors 
(NtRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), cell entry inhibitors 
or fusion inhibitors (FIs), co-receptor inhibitors (CRIs), 
and integrase inhibitors (INIs). Metabolism by the host 
organism is one of the most important determinants of the 
pharmacokinetic profile of a drug. Formation of active or 
toxic metabolites will have an impact on the pharmacolo-
gical and toxicological outcomes. Therefore, it is widely 
recognized that metabolism studies of a new chemical 
entity need to be addressed early in the drug discovery 
process. This paper describes an overview of the metabo-
lism of currently available anti-HIV drugs.
ANTI-HIV DRUGS
The antiretroviral therapy advanced with the elu-
cidation of the HIV cycle of life. Zidovudine (3’-azido-
3’-deoxythymidine or AZT) (Retrovir®), a nucleoside 
analogue, was the first anti-HIV drug. AZT was originally 
synthesized as a potential anticancer drug by Horwitz in 
1964 (Horwitz, Chua, Noel, 1964). In 1985, its anti-HIV 
activity was confirmed in vitro by a screening process 
using compounds that had previously been produced for 
others purposes (Fauci, 2003). AZT triphosphate acts by 
competitively inhibiting the utilization of thymidine tri-
phosphate by reverse transcriptase (RT) of HIV-1 (Mitsuya 
et al., 1985). In 1987, AZT was approved by the United 
States Food and Drug Administration (FDA) and supplied 
by Burroughs-Wellcome Laboratories.
In 2009, twenty-six years after the discovery of HIV 
as causative agent of AIDS, no less than twenty-five anti-
HIV compounds have been formally approved for clinical 
use in the treatment of AIDS (Table I) (Adamson, Freed, 
2009). These compounds fall into different categories, 
depending on the target within the HIV replicative cycle 
they interact with. In all, there are six categories: nucleo-
side reverse transcriptase inhibitors (NRTIs: zidovudine, 
didanosine, zalcitabine, stavudine, lamivudine, abacavir, 
emtricitabine), nucleotide reverse transcriptase inhibitors 
(NtRTIs: tenofovir), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs: nevirapine, delavirdine, efavirenz, 
etravirine), protease inhibitors (PIs: saquinavir, ritonavir, 
indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, 
fosamprenavir, tipranavir, darunavir), cell entry inhibitors 
or fusion inhibitors (FIs: enfuvirtide), co-receptor inhi-
bitors (CRIs: maraviroc), and integrase inhibitors (INIs: 
raltegravir) (Mehellou, De Clercq, 2009).
Although treatment with antiviral agents has proven 
to be a highly effective way to improve the health and 
survival of infected individuals, the epidemic will conti-
nue to grow and there is an urgent need to develop new 
anti-HIV drugs.
METABOLISM STUDIES
Metabolism of a drug is one of the most important 
determinants of its pharmacokinetic properties. In most 
cases, metabolism leads to the inactivation of drugs. 
However, the metabolic transformation of a xenobiotic 
can also sometimes lead to the generation of an active 
metabolite, which can be solely or partially responsible 
for the pharmacological response. In some instances, me-
tabolic transformation can also produce reactive or toxic 
intermediates or metabolites, with potential toxicological 
implications (Kumar, Surapaneni, 2001). Hence, a good 
understanding of the metabolism of a new chemical entity 
is needed early in the drug discovery process.
Mammalian metabolism of xenobiotics is traditio-
nally subdivided into Phase I and Phase II processes. In 
Phase I, oxidation, reduction, or hydrolysis results in the 
introduction of new functional groups. Phase II involves 
conjugation reactions, where a highly hydrophilic moiety 
such as sulfate or glucuronide is attached to make the 
compounds more water-soluble and to prepare for excre-
tion through urine or bile (Kumar, Surapaneni, 2001; Lee, 
Obach, Fisher, 2003).
The most important group of Phase I enzymes is 
the cytochrome P450 (CYP) superfamily. About 90% of 
catalysis mediated by P450 is performed by the human 
isoforms: CYPs 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 
(Guengerich, 2006). They include oxidation reactions, 
such as aromatic hydroxylation, aliphatic hydroxylation, 
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N-oxidation, oxidative desalkylation and epoxide forma-
tion (Omura, 1999).
Key Phase II enzymes include, for instance, uridine 
diphosphate-dependent glucuronosyltransferase (UGT), 
sulfotransferases and glutathione- S -transferase. Glucuro-
nidation of small lipophilic molecules by UGTs is proba-
bly the most important Phase II process for the clearance 
of drugs. Consistent with its broad substrate profile, UGT 
exists as an enzyme superfamily. So far, 18 UGT proteins, 
which can be divided into two families, UGT1 and UGT2, 
have been identified (Mackenzie et al., 1997). 
Prediction of drug metabolism in humans
In vitro and in vivo extrapolation
The ability to predict human pharmacokinetic from 
in vitro and in vivo models with a reasonable degree of 
accuracy (2.0-fold variation) is an ongoing challenge 
with many different approaches yielding varying degrees 
of success (Prakash, Vaz, 2009). Traditionally, in vivo 
drug metabolism studies have relied on the use of model 
systems to produce the expected human metabolites of 
drugs. Usually whole animal systems are used, especially 
TABLE I - Approved antiretroviral drugs in the US and Europe
Generic Name Brand Name Manufacturer Date of FDA approval
Zidovudine Retrovir GlaxoSmithKline 19 March 1987
Didanosine Videx (tablet)
Videx EC (capsule)
Bristol Myers-Squibb 
Bristol Myers-Squibb
9 October 1991
31 October 2000
Zalcitabine Hivid Hoffmann-La Roche 19 June 1992
Stavudine Zerit Bristol Myers-Squibb 24 June 1994
Lamivudine Epivir GlaxoSmithKline 17 November 1995
Saquinavir Invirase (hard gel capsule)
Fortovase (soft gel capsule)
Hoffmann-La Roche 
Hoffmann-La Roche
6 December 1995
7 November 1997
Ritonavir Norvir Abbott Laboratories 1 March 1996
Indinavir Crixivan Merck 13 March 1996
Nevirapine Viramune Boehringer Ingelheim 21 June 1996
Nelfinavir Viracept Agouron Pharmaceuticals 14 March 1997
Delavirdine Rescriptor Pfizer 4 April 1997
Efavirenz Sustiva (US)
Stocrin (Europe)
Bristol Myers-
Squibb Merck
17 September 1998
17 September 1998
Abacavir Ziagen GlaxoSmithKline 17 December 1998
Amprenavir Agenerase GlaxoSmithKline 15 April 1999
Lopinavir + ritonavir Kaletra
Aluvia (developing world)
Abbott Laboratories 
Abbott Laboratories
15 September 2000
15 September 2000
Tenofovir Viread Gilead Sciences 26 October 2001
Enfuvirtide Fuzeon Hoffmann-La Roche & Trimeris 13 March 2003
Atazanavir Reyataz Bristol-Myers Squibb 20 June 2003
Emtricitabine Emtriva Gilead Sciences 2 July 2003
Fosamprenavir Lexiva (US)
Telzir (Europe)
GlaxoSmithKline 
GlaxoSmithKline
20 October 2003
20 October 2003
Tipranavir Aptivus Boehringer Ingelheim 22 June 2005
Darunavir Prezista Tibotec, Inc. 23 June 2006
Maraviroc Celsentri (Europe)
Selzentry (US)
Pfizer
Pfizer
18 September 2007
18 September 2007
Raltegravir Isentress Merck & Co., Inc. 12 October 2007
Etravirine Intelence Tibotec Therapeutics 18 January 2008
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small laboratory animal models like rat, dog, cat, guinea 
pig, rabbit etc. However, interspecies differences must 
be considered since there is no “perfect” animal model 
destined for extrapolation to the human model. In vitro 
studies are generally used to complement and specify the 
data obtained using perfused organs, tissue or cell cultures 
and microsomal preparations. Such methods suffer from 
a number of limitations, such as the cost of experimental 
animals, the ethical concerns and species variations (Asha, 
Vidyavathi, 2009; Collins, 2001).
Isolated perfused rat liver has the advantages of 
controlling blood and bile flows, ease of manipulation of 
the perfusion medium and the large number of perfusate 
samples that may be collected (Meijer, Swart, 1997). Inste-
ad, microsomal preparations are derived from endoplasmic 
reticulum after homogenization and centrifugation and 
present CYPs and UGTs. They are developed to predict 
metabolic clearance of the compound and drug-drug inte-
ractions, and are widely used for drug metabolism studies 
(Pelkonen et al., 2005).
Another important tool employed in drug metabo-
lism is the application of human hepatocyte cultures, that 
present both Phase I and Phase II enzymes, representing 
a great model for biotransformation study mediated by 
P450, and allowing a good correlation with in vivo studies. 
On the other hand, the use of hepatocyte cultures is limi-
ted by the restricted availability of liver tissue (Li et al., 
1997; Gomez-Lechon et al., 2004). Liver-derived HepG-2 
and BC2 cell lines and lung-derived line A549 have the 
disadvantage of expressing few enzymes, restricting their 
metabolic capacity (Yoshitomi et al., 2001; Le Vee et al., 
2006). However, the recent human hepatoma-derived cell 
line HepaRG has been shown to possess functions and 
morphological resemblance to normal human hepatocytes 
(Aninat et al., 2006).
The use of microorganisms as models of mammalian 
metabolism was introduced in the early 1970s by Smith 
and Rosazza (Smith, Rosazza, 1974, 1975). This method 
uses eukaryotic microorganisms to produce metabolites si-
milar to mammals, since microbial transformation systems 
could closely mimic most of the Phase I transformations 
of drugs observed in mammals, mainly those catalyzed by 
cytochrome P450 (Azerad, 1999). 
Compared with traditional methods, there are cle-
arly a number of practical advantages in using microbial 
transformation as a model for drug metabolism, such 
as its chemo-, regio-, and stereoselectivity, impressive 
catalytic efficiency, and capability of accepting a wide 
range of complex molecules as substrates. In addition, it is 
conducive to easy scale up to produce sufficient amounts 
of metabolites for unambiguous structural determination, 
and to provide such metabolites as authentic standards 
(Zmijewski et al., 2006; Asha, Vidyavathi, 2009).
Therefore, it is a valuable tool in the production 
of molecules with improved, different or toxic activity 
originated by the fungal enzymatic biodiversity (Azerard, 
1999; Asha, Vidyavathi, 2009). Recently, our laboratory 
has carried out a number of studies applying microbial mo-
dels to study mammalian metabolism (Gomes et al., 2006; 
Pazzini et al., 2005, 2010; Carneiro et al., 2005, 2010; 
Dias et al., 2005; Costa et al., 2008; Braga et al., 2011).
In silico Computational Tools
In recent years, several in silico computational 
methods have become available for prediction of me-
tabolism and pharmacokinetics of the NCEs and are 
increasingly becoming a part of the drug discovery 
process to select candidates with desirable ADME pro-
perties (Canavan, 2007; Afzelius et al., 2007; De Graff, 
Vermeulen, Feenstra, 2005). Mechanism-based quantum 
chemical calculations on substrates and the enzyme, 
pharmacophore modeling of ligands, and protein homo-
logy modeling in combination with automated docking 
and molecular dynamics simulations have been used to 
rationalize and predict ligand binding and formation of 
metabolites (Prakash, Vaz, 2009). 
Moreover, the prediction of metabolites can be per-
formed by means of large collections of transformation 
rules. A given compound is fragmented and then passed 
through all rules to identify putative metabolically labile 
sites. Expert systems and their databases, such as Meta-
bolExpert (Darvas, 1988), META (Klopman, Dimayuga, 
Talafous, 1994), METEOR (Testa et al., 2005), MetaDrug 
(Ekins et al., 2006), and PK/DB (Moda et al., 2008), are 
examples of in silico methods used to predict drug bio-
transformation pathways and possible metabolites, that 
provide a ranked list of most likely metabolites.
Metasite (Cruciani et al., 2005) is a computational 
program for metabolite formation prediction, which com-
bines structural information, by matching the structural 
complementarity of the substrate and the protein, and 
rule-based and reactivity methods. 
The availability of more and more 3D protein 
structures of P450 paves the way for molecular modeling 
approaches that zoom in on the atomic details of enzyme-
ligand interactions. Docking is the most commonly used 
structure-based method, able to predict the site of meta-
bolism of the substrate based on which atoms are exposed 
or close to the catalytic centre (the heme iron) in order 
for metabolism to take place (Stjernschantz, Vermeulen, 
Oostenbrink, 2008). 
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ANTI-HIV DRUGS METABOLISM
Since the discovery of antiretrovirals, metabolism 
studies of these drugs have been increasingly carried 
out, aiming to ensure their efficacy and safety and to 
explain their toxic effects (Li, Chan, 1999). This trend 
is graphically illustrated in Figure 1, which presents the 
number of publications about antiretrovirals metabolism, 
between 1987 and 2009, retrieved upon searching with 
the SciFinder engine.
Nucleoside Analogue Reverse Transcriptase 
Inhibitors (NRTIs)
The reverse transcriptase (RT) of HIV is actually 
the target for three classes of inhibitors: nucleoside RT 
inhibitors (NRTIs), nucleotide RT inhibitors (NtRTIs) and 
non-nucleoside RT inhibitors (NNRTIs). The NRTIs and 
NtRTIs interact with the catalytic site (that is the substrate-
binding site) of the enzyme, whereas the NNRTIs interact 
with an allosteric site located a short distance from the 
catalytic site (De Clercq, 2007).
For the NRTIs and NtRTIs to interact with the subs-
trate-binding site they need to be phosphorylated to the tri-
phosphate and diphosphate forms, respectively. There are 
at present, seven NRTIs that have been formally approved 
for the treatment of HIV infections: zidovudine (AZT), 
didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lami-
vudine (3TC), abacavir (ABC) and emtricitabine [(-)FTC]. 
All the NRTIs can be considered 2’,3’-dideoxynucleoside 
(ddN) analogues and act in a similar fashion. After they 
have been taken up as such by the cells, they are phos-
phorylated to their 5’-mono-, 5’-di- and 5’-triphosphate 
(MP, DP and TP, respectively) form following the same 
mechanism: ddN → ddNMP → ddNDP → ddNTP, before 
the latter will then act as a competitive inhibitor/alternate 
substrate of the normal substrate dNTP (either dATP, 
dTTP, dGTP or dCTP) (Furman et al., 1986; De Clercq, 
2007). As competitive inhibitor of the normal substrate, 
the ddNTP will inhibit incorporation of this substrate into 
the growing DNA chain; as alternate substrate it will be 
incorporated into this chain (as ddNMP), thereby acting 
as a chain terminator (since the ddNMP is missing the 
3’-hydroxyl group required for further chain elongation) 
(De Clercq, 2007).
Among the NRTIs, metabolism studies have been 
focused on zidovudine (AZT). There are three main me-
tabolic pathways of AZT: intracellular phosphorylation, 
glucuronidation and reduction (Figure 2). The intracellular 
metabolism, which involves the formation of zidovudine-
5’-triphosphate (AZT-TP, 1), is limited in the last two steps 
of phosphorylation due to an inefficiency of the enzyme 
thymidine kinase to form zidovudine-5’-diphosphate 
(AZT-DP), leading to accumulation of zidovudine-5’-
monophosfate (AZT-MP) within the cell, and serving as a 
deposit for the formation of AZT-TP. High concentrations 
of AZT-MP inhibit the thymidylate kinase, decreasing 
the intracellular concentration of deoxythymidine-5’-
triphosphate and increasing the activity of antiretroviral. 
Furthermore, the accumulation of intracellular AZT-MP 
may be related to the toxicity observed during the use of 
AZT, mainly represented by hematological toxicity, likely 
caused by mitochondrial DNA polymerase γ inhibition 
(Veal, Back, 1995).
AZT undergoes fast first-pass hepatic metabolism, 
producing zidovudine-5’-glucuronide (GAZT, 2), an inac-
tive metabolite (Li, Chan, 1999). In studies using human 
microsomal preparations, it was observed that AZT’s 
glucuronidation is independent of sex or age, but the poly-
morphism displayed by UGT2B7 isoform may contribute 
to the interindividual variations observed in plasma con-
centration of AZT and its conjugate metabolite (Court et 
al., 2003). However, these variations may be involved in 
the conjugation catalyzed by other isoforms, as well as the 
stage of intracellular AZT’s phosphorylation, which implies 
a greater or lesser availability of substrate for hepatic meta-
bolism. Also, according to studies on liver microsomes, the 
extent of metabolism of AZT by UGT can range from 60 to 
75% in humans, while in rats it is only 10% (Naritomi et al., 
2003) due to higher catalytic efficiency of these enzymes in 
the former (Trapnell et al., 1998).
The third metabolic pathway of AZT consists of 
its azido group reduction, probably mediated by both 
FIGURE 1 - Graphical representation of the increasing trend for 
number of anti-HIV drugs metabolism publications, from 1987 
to October 2009 (data presented are those listed by SciFinder). 
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cytochrome P450 isoenzymes, NADPH-cytochrome 
P450 reductase and cytochrome b5 reductase, resulting in 
3’-amino-3’-deoxythymidine (AMT, 3). In studies using 
rat hepatocytes and liver microsomes of rats and humans, 
the participation of the subfamilies CYP2B, CYP3A and 
CYP4A was observed in this reaction, evidenced by an 
increased formation of AMT through the use of inducers 
of these enzymes. The CYP2C9 isoform also appears to 
be involved in this process. These studies have also indi-
cated that the AMT is five to seven times more toxic to the 
hematopoietic cells than AZT, confirming its role in the 
cytotoxicity of antiretroviral therapy observed in patients. 
In another similar study, the AMT glucuronide conjugate 
(GAMT), produced from the reduction of zidovudine-5’-
glucuronide, was found to discard the AMT as a substrate 
for UGT (Cretton et al., 1991).
AZT metabolism studies were also performed using 
microbial models obtaining derivatives not previously 
reported in the literature (Figure 3). Kruszewska and co-
workers (2003) studied the bioconversion of AZT with an 
environmental bacterium, Stenotrophomonas maltophilia 
PCM 1942. After ten days of incubation, a hydroxylated 
metabolite at the C-2’ deoxyribose ring (4) was produced 
with a yield of about 97% (Kruszewska et al., 2003). In 
our laboratory, biotransformation of AZT was performed 
using Cunninghamella echinulata ATCC 9244 as a catalyst 
(Nunes, 2008). This filamentous fungus strain is widely 
known for performing biotransformation reactions of a va-
riety of compounds, similar to mammals, and is frequently 
employed in bioconversion processes. In our experiment, 
C. echinulata produced a glycosylated metabolite of AZT 
(5) (Figure 3) after seven days of incubation, under mild 
conditions of temperature and pH, with a yield of about 
46% (Nunes, 2008).
Didanosine (2’,3’-dideoxyinosine or ddI) (Figure 
4) is first phosphorylated by 5’-nucleotidase to form 
didanosine-5’-monophosfate (ddI-MP) in human lym-
phoid cells. Then, ddI-MP is converted to dideoxyade-
nosine-5’-monophosfate (ddA-MP) by adenylosuccinate 
synthetase and lyase, with subsequent phosphorylation to 
dideoxyadenosine-5’-triphosphate (ddA-TP) by adenyla-
te kinase (miokinase), producing active metabolite (6) 
responsible for inhibiting viral reverse transcriptase. In 
another metabolic pathway, ddI is hydrolyzed by purine 
nucleoside phosphorylase, to release the sugar deoxyri-
bose (7) and hypoxanthine (8), which is degraded into 
FIGURE 2 – Main metabolic routes of zidovudine in humans.
FIGURE 3 - Microbial metabolites of AZT: AZT-2’-hydroxyl 
(4) (Kruszewska et al., 2003) and AZT-5’-glucoside (5) 
(Nunes, 2008).
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uric acid (9) and eliminated (Navé et al., 1994). In a study 
using beagle dogs, the following possible metabolites of 
didanosine were found in plasma and urine: allantoin, 
uric acid, hypoxanthine and xanthine (Kaul et al., 1993). 
Probably ddI is not metabolized by CYP450 isoforms, 
since studies using inducers of these enzymes showed no 
changed pharmacokinetic profile (Bruzzese et al., 1995).
Zalcitabine (2’,3’-dideoxycytidine or ddC), as well 
as other nucleoside analogues, must be phosphorylated 
to dideoxycitidine-5’-triphosphate (ddC-TP) in the intra-
cellular environment to become active (10) (Figure 5). The 
first stage of phosphorylation, with production of ddC-MP, 
seems to be inefficient due to a low affinity between ddC and 
the enzyme deoxycytidine kinase. In addition to the mono-, 
di- and triphosphate, the only reported metabolite of zalci-
tabine is dideoxyuridine, found in urine (Li, Chan, 1999).
Human metabolism of stavudine (2’,3’-didehydro-
2’,3’-dideoxythymidine or d4T) (Figure 6) has yet to be 
completely elucidated. Intracellularly, it is sequentially 
phosphorylated to produce its active form, stavudine-5’-
triphosphate (d4T-TP) (11). In a study using monkeys and 
isolated rat hepatocytes, the degradation of stavudine was 
detected in thymine (12) and the d4T-TP derivative, with 
subsequent production of beta aminoisobutyric acid (BAI-
BA) (13) (Cretton et al., 1993). The glucuronide metabolite 
(14) of stavudine was found in the urine of monkeys but has 
remained controversial (Schinazi, et al., 1990).
A recent study reported by our group (Freitas, 2009) 
described the metabolic profile of stavudine, applying in 
vivo, in vitro and in silico approaches. The bioconversion 
experiments with nine strains of filamentous fungi, detect-
ed one major metabolite, which was further identified as 
thymine (12). The in vivo study with Balb/c mice detected 
the same metabolite (thymine, 12), highlighting the strains 
used in this study as microbial models of stavudine metab-
olism (Figure 7). Unlike in vivo and in vitro experiments, 
the in silico study based upon the docking and molecular 
dynamics simulations of stavudine in complex with the 
active site of cytochrome P450 CYP3A4 structure, identi-
fied that the methyl group is the most probable site for the 
oxidation reaction mediated by CYP450 enzymes. It is 
likely that the in vivo and in vitro results described in this 
study must be mediated by enzymes other than CYP-450.
Lamivudine (3TC) (Figure 8) is another NRTI, 
whose intracellular phosphorylation occurs efficiently to 
produce its active metabolite, lamivudine-5’-triphosphate 
(3TC-TP) (15). There was no difference in the concen-FIGURE 4 – Proposed metabolic pathways of didanosine. 
FIGURE 5 – Metabolic scheme for zalcitabine.
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tration of 3TC and its pharmacokinetic profile in healthy 
individuals and patients with moderate to severe hepatic 
dysfunction, suggesting that lamivudine metabolism by 
liver enzymes is minimal (Johnson, Horak, Breuel, 1998).
Abacavir (ABC) (Figure 9), an analogue of 2’-deo-
xyguanosine, undergoes fast intracellular phosphorylation 
catalyzed by the enzyme adenosine phosphotransferase, 
producing its monophosphate form, which is then con-
verted into the monophosphate form of carbovir (CBV-
MP) by a cytosolic deaminase. Subsequently, CBV-MP 
is converted into the di- and triphosphate form (16), the 
latter is another analogue of deoxyguanosine with potent 
inhibitory activity of viral reverse transcriptase (Faletto 
et al., 1997).
In addition, it also undergoes hepatic biotransforma-
tion in humans, mice and monkeys, producing two major 
metabolites, identified as 5’-carboxylate (17) and 5’-glu-
curonide derivatives (18), formed by cytosolic alcohol 
dehydrogenase (ADH) and UGT, respectively (Good et 
al., 1995; McDowell et al., 1999). In in vitro experiments 
with human liver microsomes, it was demonstrated that 
CYP450 enzymes appear to be involved in the metabolism 
of abacavir (Ravitch et al., 1998).
Nucleotide Reverse Transcriptase Inhibitors 
(NtRTIS)
NtRTIs should be clearly distinguished from the 
NRTIs as they are nucleotide analogues (not nucleoside 
analogues), which means they only need two (not three) 
phosphorylation steps to be converted to their active form. 
Most importantly, they contain a phosphonate group that 
FIGURE 6 – Proposed metabolic routes of stavudine. 
FIGURE 7 – Metabolism studies of stavudine by C. elegans and 
mice, producing the metabolite thymine (Freitas, 2009).
FIGURE 8 – Intracelular metabolism of lamivudine.
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cannot be cleaved by hydrolases (esterases), which would 
make it more difficult to cleave off these compounds once 
incorporated at the 3’-terminal end, as compared to their 
regular nucleotide counterparts (i.e. AZTMP, ddAMP, 
ddCMP, etc.). The prototype of the NtRTIs, (R)-9-(2- phos-
phonomethoxypropyl) adenine (tenofovir) (Figure 10) was 
first described in 1993 (Balzarini et al., 1993) and is the 
only NtRTIs currently approved for use in patients suffe-
ring from HIV. Due to its limited oral bioavailability, teno-
fovir has been converted to its oral prodrug form, tenofovir 
disoproxil fumarate (TDF, Viread®) and has become one 
of the most frequently prescribed drugs for the treatment 
of HIV infections (De Clercq, 2003). Since 2008, it has 
also been approved for the treatment of chronic hepatitis 
B virus (HBV) infections. Tenofovir is metabolized intra-
cellularly to its active metabolite, tenofovir diphosphate 
(19), which is a competitive inhibitor of HIV-1 RT that 
terminates the growing DNA chain. Phosphorilation to its 
diphosphate form can be achieved in one or two steps with 
the aid of 5-phosphoribosyl-1-pyrophosphonate (PRPP) 
synthetase (Balzarini et al., 1995) or AMP kinase (Merta 
et al., 1992), respectively (Figure 10). 
Non-nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs)
These compounds are noncompetitive inhibitors 
of HIV-1 RT, because they act differently compared with 
nucleoside analogues. They are mainly metabolized by 
the CYP3A subfamily of cytochrome P450 enzymes. 
Nevirapine (NVP) (Figure 11), for example, is capable of 
inducing its own metabolism mediated by CYP450 with 
production of several hydroxylated metabolites, with sub-
sequent glucuronidation. These derivatives were found in 
urine and feces of human and animals (dog, mouse, rat, 
chimpanzee, rabbit and monkey), after oral administration 
of nevirapine, and identified as 2-hydroxy-nevirepine (20), 
3-hydroxy-nevirapine (21), 8-hydroxy-nevirapine (22), 
12-hydroxy-nevirapine (23), their respective glucuronide 
conjugates (24-27), and 4-carboxy-nevirapine (28), for-
med by secondary oxidation of 23 (Riska et al., 1999a, 
b). In experiments with human liver microsomes, it was 
observed that CYP3A and CYP2B6 are responsible for 2- 
and 3-hydroxy-nevirapine production, respectively, while 
the formation of 8- and 12-hydroxi-nevirapine is mediated 
by several enzymes, primarily CYP3A4 and CYP2D6 
(Erickson et al., 1999).
Delavirdine (Figure 12) is another NNRTI, whi-
ch produces various metabolites in rats (Chang et al., 
1997a), mice (Chang et al., 1997b) and monkeys (Chang 
et al., 1997c) through oxidation reactions catalyzed 
mainly by CYP450. An N-desalkylation reaction pro-
duces the desalkyl delavirdine metabolite (29), with 
subsequent sulfation (30), while hydroxylation at C-6’ 
position of the pyrimidinic ring produces 6’-hydroxy-
delavirdine (31), followed by glucuronidation to form the 
FIGURE 9 – Main metabolic pathways of abacavir in humans.
FIGURE 10 – Metabolism of tenofovir.
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6’-O-glucuronide conjugate (32). The cleavage of pyrimi-
dinic ring of 6’-hydroxy-delavirdine was also observed, 
resulting in depyridinyl delavirdine, and cleavage of the 
amide bond forming indole carboxylic acid (33) and N-
isopropylpyridinepiperazine (34). Moreover, 6’-hydroxy 
delavirdine is sulfated (35) in rats, depyridinyl delavirdine 
is conjugated in rats and mice, and desalkyl delavirdine 
is hydroxylated at positions C-4’ (36) and C-6’ (37) of the 
pyrimidinic ring in rats and monkeys, with subsequent 
sulfation (38 and 39). 
In mice, N-desalkylation of N -isopropylpyridine-
piperazine produces N-deisopropylpyridinepiperazine, 
while the indole carboxylic acid undergoes conjugation. 
In monkeys, three additional metabolites were observed, 
identified as conjugation of desalkyl delavirdine with N-
acetylglucosamine, hydroxylation of delavirdine at the C-4 
position of the indole ring to form 4-hydroxy delavirdine, 
followed by glucuronidation of 4-O-glucuronide, and 
N-glucuronidation of the indole ring of delavirdine. The 
N-desalkylation was the major metabolic fate in rats and 
monkeys, while in mice it was the cleavage of the amide 
bond (Chang et al., 1997a, b, c).
Experiments with human liver microsomes sho-
wed that delavirdine is an inhibitor of the isoforms 
CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and that 
the N-desalkylation reaction is mediated by CYP2D6 and 
CYP3A4, while hydroxylation at position C-6’ of pyrimi-
dinic ring is catalyzed mainly by CYP3A4 (Voorman et 
al., 1998a, b; Voorman et al., 2001).
Efavirenz (EFV) (Figure 13) is extensively metabo-
lized and small or insignificant amounts of the unchanged 
drug were found in urine of several species, including 
humans (Mutlib et al., 1999). The major metabolite 
isolated is the O-glucuronide (40) conjugate of the me-
tabolite 8-hydroxy-efavirenz (41). EFV also undergoes 
glucuronidation to form the N-glucuronide conjugate 
(42). The sulfation of 8-hydroxy-efavirenz (43) occurs 
in all species, except humans, while EFV hydroxylation 
to form 7-hydroxy-efavirenz (44), with subsequent glu-
curonidation (45) or sulfation (46), is not only observed 
in rats. Other reactions include the hydroxylation of the 
cyclopropane ring (C-14) of 8-hydroxy-efavirenz, produ-
cing 8,14-dihydroxy-efavirenz (47), and hydroxylation 
of its sulfated conjugate (48), which can also be formed 
from the sulfation of 47, followed by glucuronidation (49) 
or conjugation with glutathione (GSH), with subsequent 
degradation, forming the adducts cysteinylglicine and 
cysteine. The hydroxylation of 44 is also observed, follo-
wed by glucuronidation (50) or sulfation (51) in position 
C-7 whereas 57 can still undergo glucuronidation (52) in 
position C-8 (Mutlib et al., 1999).
In vitro experiments using human liver microsomes 
have shown that 8-hydroxy-efavirenz was obtained as the 
major metabolite, as well as during in in vivo studies, while 
the metabolites 8,14-dihydroxy-efavirenz and 7-hydroxy-
efavirenz were also isolated. It was further demonstrated 
FIGURE 11 – Main metabolic routes of nevirapine.
FIGURE 12 – Main metabolic routes of delavirdine.
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that CYP2B6 is the major isoform responsible for the 
production of 8-hydroxy-efavirenz and 8,14-dihydroxy-
efavirenz, and that other isoforms (CYPs 1A2, 3A4 and 
3A5) seem to participate in a minority of this process 
(Ward et al., 2003). Rodriguez-Novoa and co-workers 
(2005) reported that CYP2B6 genetic polymorphisms 
contribute to variations in plasma concentration of EFV, 
proving the involvement of this isoform in its metabolism. 
In addition to being metabolized by CYP2B6, efavi-
renz is also its inhibitor, as well as its major metabolite, 
8-hydroxy-efavirenz (Bumpus et al., 2006), which is also 
an inducer of the isoform CYP3A4 (Mouly et al., 2002). 
Protease Inhibitors (PIs)
At present, there are ten protease inhibitors (PIs) 
licensed for clinical use in the treatment of HIV infections. 
With the exception of tipranavir (which is based on a cou-
marine scaffold), all these PIs are based on the “peptidomi-
metic” principle, that is they contain an hydroxyethylene 
scaffold which mimics the normal peptide linkage (cleaved 
by the HIV protease) but which can itself not be cleaved. 
They thus prevent the HIV protease from carrying out its 
normal function, which is the proteolytic processing of 
precursor viral proteins into mature viral proteins. The ten 
PIs presently available for the treatment of HIV infections 
are saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, 
lopinavir, atazanavir, fosamprenavir, tipranavir and daru-
navir (Madruga et al., 2007; Lazzarin et al., 2007).
Akin to NNRTIs, PIs are usually metabolized by 
oxidation mediated by CYP450. Saquinavir (SQV) (Fi-
gure 14) has low oral bioavailability due to its extensive 
first-pass metabolism, which occurs mainly by CYP3A4 in 
small intestine, but also in liver, producing the same meta-
bolites mono- and dihydroxy. In incubations of saquinavir 
with human small intestine and liver microsomes, two ma-
jor metabolites (53 and 54) were isolated, produced from 
mono-hydroxylations of octahydro-2-(1H)-isoquinolynil 
and (1,1-dimethylethyl)amino, respectively. Another five 
minority metabolites were found (Flitzsimmons, Collins, 
1997). One of the major metabolites was subsequently 
identified as 6-equatorial-hydroxy-saquinavir (Eaglings 
et al., 2002).
Biotransformation of indinavir (IDV) (Figure 14) 
takes place primarily in liver by CYP3A4 (Chiba et al., 
1996; Lin et al., 1996), and can also occur in the small 
intestine. Oxidative metabolites were found in both in vivo 
and in vitro experiments using liver and intestinal microso-
mes of humans and rats (Chiba, Hensleigh, Lin, 1997). In a 
study with healthy volunteers, seven major metabolites were 
found in urine, whose metabolic pathways were identified 
as: nitrogen pyridine glucuronidation (55); N-oxidation of 
pyridine (56); p-hydroxylation of the phenylmethyl radical 
(57); 3’-hydroxylation of indan (58 and 59); and N-depyrido 
methylation (Balani et al., 1995). In experiments with liver 
microsomes, the production of the metabolite cis-(indan) 
hydroxylated by isoforms of the CYP2D subfamily was 
observed in Rhesus and Cynomolgus monkeys, while 
trans-(indan) hydroxylation and N-desalkylation were 
also observed in chimpanzees and humans, mediated by 
CYP3A4. The extent of metabolism in humans was the 
lowest among the four species studied (Chiba et al., 2000).
Anari and co-workers (2004) described the meta-
bolic profile of indinavir, combining data obtained after 
analysis of human liver post-mitochondrial preparations 
in liquid chromatography coupled to mass spectroscopy 
(LC-MS/MS), and metabolic predictions generated by 
research based on structural similarity using the MDL 
Metabolite Database software. Two desalkylated, eleven 
monoxydated, three deoxygenated and two desalkylated/
monoxydated metabolites were identified, and the major 
derivatives resulted from the oxidation of pyridine, in-
danyl and fenylmethyl groups, and from N-desalkylation 
of piperazinil (Anari et al., 2004). Similar metabolites 
were found previously in another experiment employing 
LC-MS/MS analysis of the metabolites obtained from in 
vitro study (Yu, Cui, Davis, 1999).
Ritonavir (Figure 14) is extensively metabolized by 
rat, dog and human livers, through a variety of oxidative 
pathways and conjugation with glucuronic acid (60). The 
latter was only observed in dogs. The major metabolites 
identified in urine and feces of these three species were 
FIGURE 13 – Main metabolites of efavirenz.
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produced by loss of the thiazolyl carbamate, oxidation 
and loss of isopropyl-thiazolyl (61). Moreover, there 
was formation of N-hydroxymethyl urea (62), oxidation 
of the thiazolyl heteroatom (63) and a second oxidation 
of isopropyl of 61 (64), in rats only, as well as oxidation 
of the methyl thiazolyl from the metabolite that lost the 
carbamate thiazolyl, in dogs, loss of formaldehyde from 
62 in rats and dogs, producing N-demethyl urea followed 
by oxidation to produce N-hydroxy urea. Glucuronidation 
of 62 was also observed in dogs (65). In vitro experiments 
demonstrated that the metabolite 61 and the metabolite 
that lost the isopropyl-thiazolyl group have antiretroviral 
activity (Denissen et al., 1997). A study using human liver 
microsomes showed that the production of 61 is mediated 
by enzymes of the CYP3A subfamily and by the isoform 
CYP2D6 (Kumar et al., 1996). In addition to being meta-
bolized by CYP3A, ritonavir is also a potent inhibitor of 
this subfamily (Kumar et al., 1999).
Nelfinavir (NFV) (Figure 14) is biotransformed in 
the liver into three major metabolites, identified as nelfina-
vir-hydroxy-t-butyl-amide (66), 3,4-dihydroxy-nelfinavir 
(67) and 3-methoxy-4-hydroxy-nelfinavir (68) (Zhang et 
al., 1998). Compound 66 shows antiretroviral activity in 
vitro comparable to that of NFV, contributing to its oral 
activity in anti-HIV therapy, while 68 showed low activity 
(Zhang et al., 2001; Hirani, Raucy, Lasker, 2004). It has 
been shown that CYP3A4 is involved in the formation of 
metabolites 67 and 68, while 66 is produced by CYP2C19 
(Wu et al., 1998; Lillibridge et al., 1998; Khaliq et al., 
2000). 66 can also be metabolized by CYP3A4. Nelfinavir 
is also an inhibitor of CYP3A4 (Lillibridge et al., 1998) 
and CYP2B6 (Hesse et al., 2001) isoforms.
Amprenavir (Figure 14) is primarily oxidized in 
the liver by enzymes CYP450 (Decker et al., 1998). 
Experiments with human liver microsomes showed the 
production of five metabolites, the majority obtained by 
FIGURE 14 – Main metabolites of protease inhibitors, saquinavir, indinavir, ritonavir, nelfinavir and amprenavir.
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oxidation of the tetrahydrofuran ring (THF) (69). The 
others were formed by N-desalkylation (70), oxidation of 
the aliphatic chain (71), dehydration of the THF ring (72) 
and mono-oxidation of the aniline ring (73). Enzymes of 
CYP3A subfamily appear to be involved in the formation 
of 69, 71 and 73, while CYP2C9 contributes to the achie-
vement of 71. It was also observed that the metabolism of 
amprenavir is reduced in neonates due to non-maturation 
of CYPs 3A4 and 3A5 (Tréluyer et al., 2003).
Fusion Inhibitors (FIs)
Enfuvirtide is the only fusion inhibitor (FI) appro-
ved (March 2003) by the US FDA, and to be licensed for 
the treatment of HIV-1 infection in the US, Australia and 
Europe (Fletcher, 2003). This compound is a synthetic 
polypeptide of 36 amino acids that is homologous to, and 
engages in a coil-coil interaction, with the heptad repeat 
(HR) regions of the viral glycoprotein gp41 (Matthews et 
al., 2004). As a consequence of this interaction, the fusion 
of the virus particle with the outer cell membrane is blo-
cked. The FI enfuvirtide is the only anti-HIV compound 
that has a polymeric (i.e. polypeptidic) structure (structure 
not disclosed), and hence, is not orally bioavailable: it 
has to be injected parenterally (subcutaneously) twice 
daily. This makes the long-term use of enfuvirtide cum-
bersome and problematic. Enfuvirtide is primarily used 
in salvage therapy as part of drug combination regimens. 
Because enfuvirtide is a peptide, it is expected to undergo 
catabolism rather than metabolism by cytochrome P450 
enzymes (Ferraiolo, Mohler, Gloff, 1992). Enfuvirtide did 
not inhibit the activities of CYP1A2, CYP2C19, CYP2D6, 
CYP2E1 or CYP3A4 in an open label, crossover trial in 
12 HIV-infected adults (Hammer et al., 2006).
Co-Receptor Inhibitors (CRIs)
Co-receptor inhibitors (CRIs) interact with the co-
receptor CCR5 or CXCR4 used by M (macrophage)-tropic 
and T (lymphocyte)-tropic HIV strains, respectively (now 
generally termed R5 and X4 strains, respectively), to enter 
the target cells. Within the whole virus-cell entry process, 
the interaction of the viral glycoprotein gp120 and the 
co-receptor falls between the interaction of the viral glyco-
protein gp120 and the CD4 receptor, and the fusion of 
the viral glycoprotein gp41 with the outer cell membrane 
(Westby, van der Ryst, 2005). There is, at present, only one 
CRI available (licensed in 2007 for clinical use), namely, 
the CCR5 antagonist maraviroc (Perros, 2007). The major 
problem with CCR5 antagonists is that they are only active 
against R5 HIV strains, and that from a mixed population 
of X4/R5 HIV strains, they stimulate the selection of X4 
strains. Ideally, a CCR5 antagonist should be combined 
with a CXCR4 antagonist so as to block both X4 and R5 
HIV strains (Door et al., 2005). 
Maraviroc is rapidly absorbed and extensively meta-
bolized, although unchanged drug is the major circulating 
component in plasma and is the major excreted component 
after oral dosing. The metabolite profiling of plasma, urine 
and fecal samples showed that maraviroc is extensively 
metabolized with the major pathways involving oxidation 
and N-dealkylation reactions (Figure 15) (Walker et al., 
2005; Abel et al., 2008). The most abundant metabolite 
detected in human plasma was a secondary amine product 
of N-dealkylation (74, Figure 15). Moreover, Hyland and 
co-workers (2008) have demonstrated that maraviroc is 
predominantly metabolized by CYP3A4, and is not itself 
an inhibitor of CYP enzymes.
Integrase Inhibitors (INIs)
Although the integrase has been pursued for many 
years as a potential target for the development of new anti-
HIV compounds, the first integrase inhibitor (INI) licensed 
to treat HIV-1 infection, raltegravir, has only recently (in 
late 2007) been approved. The HIV integrase has essen-
tially two important catalytic functions (3’-processing 
and strand transfer) (Chiu, Davies, 2004). Raltegravir 
(Figure 16) is targeted at the strand transfer reaction, as 
is elvitegravir (Figure 16), which is now entering phase 
III clinical trials. Elvitegravir is intended for once daily 
dosing (orally), while raltegravir has to be administered 
twice daily. It has proven highly effective in reducing viral 
loads in HIV-infected patients (Grinsztejn et al., 2007; 
Steigbigel et al., 2008; Cooper et al., 2008).
In preclinical studies, raltegravir was metabolized 
predominantly in the liver via the UDP-glucuronosyltrans-
ferase (UGT)-mediated pathway. In vivo and in vitro studies 
using isoform selective chemical inhibitors and cDNA-ex-
pressed UGTs showed that UGT1A1 is the primary enzyme 
responsible for the formation of raltegravir-glucuronide (87) 
(Merck & Co, 2007; Kassahun et al., 2007). In vitro studies 
demonstrate that raltegravir is not a substrate for cytochro-
me P450 (CYP) enzymes and does not inhibit CYP1A2, 
2B6, 2C8, 2C9, 2C19, 2D6, or 3A or induce 3A4 (Iwamoto 
et al., 2008). Similarly, raltegravir is not an inhibitor of 
UGTs (UGT1A1 and UGT2B7) or P-glycoprotein (P-gp)-
mediated transport (Merck & Co, 2007).
In clinical studies, metabolism via UGT1A1-me-
diated glucuronidation is the major pathway of elimina-
tion of raltegravir, with a minor component of elimina-
tion via kidney (∼9% of total dose excreted unchanged 
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into urine). The only metabolite detected in humans 
was the phenolic hydroxyl glucuronide (87), and this 
metabolite does not have antiviral activity (Kassahun 
et al., 2007) (Figure 16). In a human ADME study, ∼51 
and 32% of a radiolabeled raltegravir dose (parent and 
metabolite) was excreted in the feces and urine, res-
pectively. The major circulating entity in plasma was 
the parent compound (69% of the total drug-related 
material in plasma), whereas most of the drug-related 
material in urine was accounted for by the glucuronide 
derivative (72% of the drug-related material in urine). 
In feces, only parent compound was detected, but it is 
likely that a good proportion of the raltegravir detected 
in feces is derived from hydrolysis of the glucuronide 
derivative secreted in bile as observed in preclinical 
species (Kassahun et al., 2007).
Elvitegravir undergoes metabolism primarily by 
CYP3A and also by glucuronidation via UGT1A1/3, 
which is the major pathway of elimination. Metabolites 
formed by these pathways are markedly less potent (5- to 
38-fold) than the parent drug and are present in plasma at 
lower concentrations; thus, the metabolites do not contri-
bute to the antiviral activity of elvitegravir (Ramanathan 
et al., 2007a).
FIGURE 15 – Proposed metabolic pathways for maraviroc.
FIGURE 16 – Structures of raltegravir, its glucuronide 
metabolite and elvitegravir.
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In a human ADME study with radiolabeled elvi-
tegravir and boosting doses of ritonavir, >90% of the 
circulating plasma was present as the parent compound. 
Radiolabeled compound was excreted primarily in the 
feces (94.8%), with a minor amount in the urine (6.7%). 
Fecal radioactivity consisted primarily of parent com-
pound (36%) and an oxidative metabolite (46%). Urine 
contained low levels of various metabolites (Ramanathan 
et al., 2007b).
FINAL CONSIDERATIONS
Despite the significant advances made in understan-
ding the mechanism of HIV infection and in identifying 
effective treatment approaches, the search for optimum 
treatment strategies for AIDS remains a major challenge.
This review has demonstrated that the cytochrome 
P450 family of enzymes is responsible for the metabolism 
of the majority of antiretroviral drugs, but for some of 
the nucleoside reverse transcriptase inhibitors (NRTIs), 
hepatic conjugation via UDP-glucuronosyltransferases 
as well as via alcohol dehydrogenase is important. NRTIs 
are the most studied class of anti-HIV agents in terms of 
metabolism. In contrast, limited published data are cur-
rently available on the other classes of anti-HIV agents 
and much of the available information is obtained from 
manufacturers and the clinical studies sponsored by the 
manufacturers. More systematic studies on metabolism, 
such as metabolite formation, the presence of active me-
tabolites and mechanisms of chemical toxicity, are needed 
regarding antiretroviral therapy.
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